1
|
Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, Guivel-Benhassine F, Staropoli I, Chazal M, Dufloo J, Planas D, Buchrieser J, Rajah MM, Robinot R, Porrot F, Albert M, Chen KY, Crescenzo-Chaigne B, Donati F, Anna F, Souque P, Gransagne M, Bellalou J, Nowakowski M, Backovic M, Bouadma L, Le Fevre L, Le Hingrat Q, Descamps D, Pourbaix A, Laouénan C, Ghosn J, Yazdanpanah Y, Besombes C, Jolly N, Pellerin-Fernandes S, Cheny O, Ungeheuer MN, Mellon G, Morel P, Rolland S, Rey FA, Behillil S, Enouf V, Lemaitre A, Créach MA, Petres S, Escriou N, Charneau P, Fontanet A, Hoen B, Bruel T, Eloit M, Mouquet H, Schwartz O, van der Werf S. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med 2020; 12:eabc3103. [PMID: 32817357 PMCID: PMC7665313 DOI: 10.1126/scitranslmed.abc3103] [Citation(s) in RCA: 176] [Impact Index Per Article: 44.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2020] [Accepted: 08/13/2020] [Indexed: 12/14/2022]
Abstract
It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we performed a pilot study of four serological assays to assess the amounts of anti-SARS-CoV-2 antibodies in serum samples obtained from 491 healthy individuals before the SARS-CoV-2 pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. We used two ELISA assays that recognized the full-length nucleoprotein (N) or trimeric spike (S) protein ectodomain of SARS-CoV-2. In addition, we developed the S-Flow assay that recognized the S protein expressed at the cell surface using flow cytometry, and the luciferase immunoprecipitation system (LIPS) assay that recognized diverse SARS-CoV-2 antigens including the S1 domain and the carboxyl-terminal domain of N by immunoprecipitation. We obtained similar results with the four serological assays. Differences in sensitivity were attributed to the technique and the antigen used. High anti-SARS-CoV-2 antibody titers were associated with neutralization activity, which was assessed using infectious SARS-CoV-2 or lentiviral-S pseudotype virus. In hospitalized patients with COVID-19, seroconversion and virus neutralization occurred between 5 and 14 days after symptom onset, confirming previous studies. Seropositivity was detected in 32% of mildly symptomatic individuals within 15 days of symptom onset and in 3% of healthy blood donors. The four antibody assays that we used enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in different subpopulations within one region.
Collapse
Affiliation(s)
- Ludivine Grzelak
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Creteil, France
- Université de Paris, Sorbonne Paris Cité, Paris, France
| | - Sarah Temmam
- Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France
| | - Cyril Planchais
- Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, INSERM U1222, Paris, France
| | - Caroline Demeret
- Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Université de Paris, Paris, France
| | - Laura Tondeur
- Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Paris, France
| | - Christèle Huon
- Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France
| | - Florence Guivel-Benhassine
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Creteil, France
| | - Isabelle Staropoli
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Creteil, France
| | - Maxime Chazal
- Department of Virology, Institut Pasteur, Paris, France
| | - Jeremy Dufloo
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Creteil, France
- Université de Paris, Sorbonne Paris Cité, Paris, France
| | - Delphine Planas
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Creteil, France
| | - Julian Buchrieser
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Creteil, France
| | - Maaran Michael Rajah
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Creteil, France
- Université de Paris, Sorbonne Paris Cité, Paris, France
| | - Remy Robinot
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Creteil, France
| | - Françoise Porrot
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Creteil, France
| | - Mélanie Albert
- Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Université de Paris, Paris, France
- National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France
| | - Kuang-Yu Chen
- RNA Biology of Influenza Virus, Department of Virology, Institut Pasteur, Paris, France
| | - Bernadette Crescenzo-Chaigne
- Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Université de Paris, Paris, France
| | - Flora Donati
- Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Université de Paris, Paris, France
- National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France
| | - François Anna
- Pasteur-TheraVectys joined unit, Institut Pasteur, Paris, France
| | - Philippe Souque
- Molecular Virology and Vaccinology Unit, Department of Virology, Institut Pasteur, Paris, France
| | | | - Jacques Bellalou
- Plate-Forme Technologique Production et Purification de Protéines Recombinantes, Institut Pasteur, Paris, France
| | - Mireille Nowakowski
- Plate-Forme Technologique Production et Purification de Protéines Recombinantes, Institut Pasteur, Paris, France
| | - Marija Backovic
- Structural Virology Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
| | - Lila Bouadma
- Université of Paris, INSERM UMR 1137 IAME, Paris, France
- Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude-Bernard University Hospital, Paris, France
| | - Lucie Le Fevre
- Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude-Bernard University Hospital, Paris, France
| | - Quentin Le Hingrat
- Université of Paris, INSERM UMR 1137 IAME, Paris, France
- Department of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude-Bernard University Hospital, Paris, France
| | - Diane Descamps
- Université of Paris, INSERM UMR 1137 IAME, Paris, France
- Department of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude-Bernard University Hospital, Paris, France
| | - Annabelle Pourbaix
- Department of Infectious Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude-Bernard University Hospital, Paris, France
| | - Cédric Laouénan
- Université of Paris, INSERM UMR 1137 IAME, Paris, France
- Department of Epidemiology, Biostatistics and Clinical Research, Assistance Publique-Hôpitaux de Paris, Bichat-Claude-Bernard University Hospital, INSERM CIC-EC 1425, Paris, France
| | - Jade Ghosn
- Université of Paris, INSERM UMR 1137 IAME, Paris, France
- Department of Infectious Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude-Bernard University Hospital, Paris, France
| | - Yazdan Yazdanpanah
- Université of Paris, INSERM UMR 1137 IAME, Paris, France
- Department of Infectious Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude-Bernard University Hospital, Paris, France
| | - Camille Besombes
- Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Paris, France
| | - Nathalie Jolly
- Investigation Clinique et Accès aux Ressources Biologiques (ICAReB), Center for Translational Research, Institut Pasteur, Paris, France
| | - Sandrine Pellerin-Fernandes
- Investigation Clinique et Accès aux Ressources Biologiques (ICAReB), Center for Translational Research, Institut Pasteur, Paris, France
| | - Olivia Cheny
- Investigation Clinique et Accès aux Ressources Biologiques (ICAReB), Center for Translational Research, Institut Pasteur, Paris, France
| | - Marie-Noëlle Ungeheuer
- Investigation Clinique et Accès aux Ressources Biologiques (ICAReB), Center for Translational Research, Institut Pasteur, Paris, France
| | - Guillaume Mellon
- Unité Coordination du Risque Epidémique et Biologique, AP-HP, Hôpital Necker, Paris, France
| | - Pascal Morel
- Etablissement Français du Sang (EFS), Paris, France
| | - Simon Rolland
- Service de maladies infectieuses, hôpital universitaire Cavale Blanche, Brest, France
- CIC 1417, CIC de vaccinologie Cochin-Pasteur, AP-HP, Hôpital Cochin, Paris, France
| | - Felix A Rey
- Structural Virology Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
| | - Sylvie Behillil
- Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Université de Paris, Paris, France
- National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France
| | - Vincent Enouf
- Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Université de Paris, Paris, France
- National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France
| | - Audrey Lemaitre
- Direction alerte et crises, réserve sanitaire, Santé publique France, Saint-Maurice, France
| | - Marie-Aude Créach
- Centre d'épidémiologie et de santé publique des armées, Marseille, France
- Direction Générale de la Santé, Paris, France
| | - Stephane Petres
- Plate-Forme Technologique Production et Purification de Protéines Recombinantes, Institut Pasteur, Paris, France
| | | | - Pierre Charneau
- Pasteur-TheraVectys joined unit, Institut Pasteur, Paris, France
- Molecular Virology and Vaccinology Unit, Department of Virology, Institut Pasteur, Paris, France
| | - Arnaud Fontanet
- Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Paris, France
- PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France
| | - Bruno Hoen
- Direction de la recherche médicale, Institut Pasteur, Paris, France
| | - Timothée Bruel
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Creteil, France
| | - Marc Eloit
- Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France.
- National Veterinary School of Alfort, Maisons-Alfort, France
| | - Hugo Mouquet
- Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, INSERM U1222, Paris, France
| | - Olivier Schwartz
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France.
- Vaccine Research Institute, Creteil, France
| | - Sylvie van der Werf
- Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Université de Paris, Paris, France
- National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France
| |
Collapse
|